Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127


Induction of autophagy-dependent apoptosis in cancer cells through activation of ER stress: an uncovered anti-cancer mechanism by anti-alcoholism drug disulfiram.

Zhang X, Hu P, Ding SY, Sun T, Liu L, Han S, DeLeo AB, Sadagopan A, Guo W, Wang X.

Am J Cancer Res. 2019 Jun 1;9(6):1266-1281. eCollection 2019.


Do midwifery International clinical placements influence students' practice and employment decisions?

Geraghty S, Davison C, DeLeo A, Bloxsome D.

Women Birth. 2019 Mar 21. pii: S1871-5192(18)30615-2. doi: 10.1016/j.wombi.2019.03.003. [Epub ahead of print]


Midwifery student's perceptions of caring for substance-using pregnant women.

Doleman G, Geraghty S, DeLeo A.

Nurse Educ Today. 2019 May;76:26-30. doi: 10.1016/j.nedt.2019.01.027. Epub 2019 Feb 6.


Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer.

Albers AE, Qian X, Kaufmann AM, Mytilineos D, Ferris RL, Hoffmann TK, DeLeo AB.

Sci Rep. 2018 Jul 16;8(1):10716. doi: 10.1038/s41598-018-29067-5.


Tau Phosphorylation is Impacted by Rare AKAP9 Mutations Associated with Alzheimer Disease in African Americans.

Ikezu T, Chen C, DeLeo AM, Zeldich E, Fallin MD, Kanaan NM, Lunetta KL, Abraham CR, Logue MW, Farrer LA.

J Neuroimmune Pharmacol. 2018 Jun;13(2):254-264. doi: 10.1007/s11481-018-9781-x. Epub 2018 Mar 7.


iMidwife: midwifery students' use of smartphone technology as a mediated educational tool in clinical environments.

DeLeo A, Geraghty S.

Contemp Nurse. 2018 Aug - Oct;54(4-5):522-531. doi: 10.1080/10376178.2017.1416305. Epub 2017 Dec 18.


Extracellular Vesicle Biology in Alzheimer's Disease and Related Tauopathy.

DeLeo AM, Ikezu T.

J Neuroimmune Pharmacol. 2018 Sep;13(3):292-308. doi: 10.1007/s11481-017-9768-z. Epub 2017 Nov 28. Review.


A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram.

Cong J, Wang Y, Zhang X, Zhang N, Liu L, Soukup K, Michelakos T, Hong T, DeLeo A, Cai L, Sabbatino F, Ferrone S, Lee H, Levina V, Fuchs B, Tanabe K, Lillemoe K, Ferrone C, Wang X.

Cancer Lett. 2017 Nov 28;409:9-19. doi: 10.1016/j.canlet.2017.08.028. Epub 2017 Aug 30.


Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma.

Cai L, Michelakos T, Ferrone CR, Zhang L, Deshpande V, Shen Q, DeLeo A, Yamada T, Zhang G, Ferrone S, Wang X.

Oncotarget. 2017 Jun 6;8(23):37646-37656. doi: 10.18632/oncotarget.16841.


Targeting cancer stem cells with p53 modulators.

Zhang Z, Liu L, Gomez-Casal R, Wang X, Hayashi R, Appella E, Kopelovich L, DeLeo AB.

Oncotarget. 2016 Jul 19;7(29):45079-45093. doi: 10.18632/oncotarget.8650.


Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice.

Sobo-Vujanovic A, Vujanovic L, DeLeo AB, Concha-Benavente F, Ferris RL, Lin Y, Vujanovic NL.

Cancer Immunol Res. 2016 May;4(5):441-51. doi: 10.1158/2326-6066.CIR-15-0104. Epub 2016 Feb 19.


Blocking the formation of radiation-induced breast cancer stem cells.

Wang Y, Li W, Patel SS, Cong J, Zhang N, Sabbatino F, Liu X, Qi Y, Huang P, Lee H, Taghian A, Li JJ, DeLeo AB, Ferrone S, Epperly MW, Ferrone CR, Ly A, Brachtel EF, Wang X.

Oncotarget. 2014 Jun 15;5(11):3743-55.


Prospective identification and purification of quiescent adult neural stem cells from their in vivo niche.

Codega P, Silva-Vargas V, Paul A, Maldonado-Soto AR, Deleo AM, Pastrana E, Doetsch F.

Neuron. 2014 May 7;82(3):545-59. doi: 10.1016/j.neuron.2014.02.039.


Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL, Ferris RL.

Clin Cancer Res. 2014 May 1;20(9):2433-44. doi: 10.1158/1078-0432.CCR-13-2617. Epub 2014 Feb 28.


The role of the FESSH Hand Trauma Committee in Europe.

Battiston B, LetiAcciaro A, DeLeo A.

Handchir Mikrochir Plast Chir. 2013 Dec;45(6):326-31. doi: 10.1055/s-0033-1361100. Epub 2013 Dec 19.


PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions.

Szczepanski MJ, DeLeo AB, Łuczak M, Molinska-Glura M, Misiak J, Szarzynska B, Dworacki G, Zagor M, Rozwadowska N, Kurpisz M, Krzeski A, Kruk-Zagajewska A, Kopec T, Banaszewski J, Whiteside TL.

Oral Oncol. 2013 Feb;49(2):144-51. doi: 10.1016/j.oraloncology.2012.08.005. Epub 2012 Sep 1.


17β Hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma.

Szajnik M, Szczepanski MJ, Elishaev E, Visus C, Lenzner D, Zabel M, Glura M, DeLeo AB, Whiteside TL.

Gynecol Oncol. 2012 Dec;127(3):587-94. doi: 10.1016/j.ygyno.2012.08.010. Epub 2012 Aug 17.


Targeting cancer stem cells with ALDH1A1-based immunotherapy.

Deleo AB.

Oncoimmunology. 2012 May 1;1(3):385-387.


Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy.

Khoury T, Ademuyiwa FO, Chandrasekhar R, Jabbour M, Deleo A, Ferrone S, Wang Y, Wang X.

Mod Pathol. 2012 Mar;25(3):388-97. doi: 10.1038/modpathol.2011.172. Epub 2011 Nov 11. Erratum in: Mod Pathol. 2012 Jun;25(6):917. Chandraseekhar, Rameela [corrected to Chandrasekhar, Rameela].


A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.

Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, Gooding W, Visus C, Deleo AB, Wolf JK, Bell JG, Berzofsky JA, Whiteside TL, Khleif SN.

Cancer Immunol Immunother. 2012 Mar;61(3):373-84. doi: 10.1007/s00262-011-1100-9. Epub 2011 Sep 17.


Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells.

Visus C, Wang Y, Lozano-Leon A, Ferris RL, Silver S, Szczepanski MJ, Brand RE, Ferrone CR, Whiteside TL, Ferrone S, DeLeo AB, Wang X.

Clin Cancer Res. 2011 Oct 1;17(19):6174-84. doi: 10.1158/1078-0432.CCR-11-1111. Epub 2011 Aug 19.


Identification of Hydroxysteroid (17β) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas.

Visus C, Ito D, Dhir R, Szczepanski MJ, Chang YJ, Latimer JJ, Grant SG, DeLeo AB.

Cancer Immunol Immunother. 2011 Jul;60(7):919-29. doi: 10.1007/s00262-011-1001-y. Epub 2011 Mar 16.


CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck.

Andrade Filho PA, Ito D, Deleo AB, Ferris RL.

Cancer Immunol Immunother. 2010 Oct;59(10):1561-8. doi: 10.1007/s00262-010-0886-1. Epub 2010 Jun 25.


CSPG4 in cancer: multiple roles.

Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, Ferrone CR, Favoino E, Koya Y, Campoli MR, McCarthy JB, DeLeo AB, Ferrone S.

Curr Mol Med. 2010 Jun;10(4):419-29. Review.


Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.

Hendrickson RC, Cicinnati VR, Albers A, Dworacki G, Gambotto A, Pagliano O, Tüting T, Mayordomo JI, Visus C, Appella E, Shabanowitz J, Hunt DF, DeLeo AB.

Cancer Immunol Immunother. 2010 Jan;59(1):113-24. doi: 10.1007/s00262-009-0730-7. Epub 2009 Jun 27.


Spontaneous apoptosis of tumor-specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer.

Albers AE, Schaefer C, Visus C, Gooding W, DeLeo AB, Whiteside TL.

Head Neck. 2009 Jun;31(6):773-81. doi: 10.1002/hed.21031.


CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer.

Chikamatsu K, Sakakura K, Takahashi G, Okamoto A, Furuya N, Whiteside TL, DeLeo AB, Masuyama K.

Cancer Immunol Immunother. 2009 Sep;58(9):1441-8. doi: 10.1007/s00262-009-0661-3. Epub 2009 Jan 28.


A comparison of rearfoot motion control and comfort between custom and semicustom foot orthotic devices.

Davis IS, Zifchock RA, Deleo AT.

J Am Podiatr Med Assoc. 2008 Sep-Oct;98(5):394-403.


Development of multi-epitope vaccines targeting wild-type sequence p53 peptides.

DeLeo AB, Whiteside TL.

Expert Rev Vaccines. 2008 Sep;7(7):1031-40. doi: 10.1586/14760584.7.7.1031. Review.


Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck.

Visus C, Ito D, Amoscato A, Maciejewska-Franczak M, Abdelsalem A, Dhir R, Shin DM, Donnenberg VS, Whiteside TL, DeLeo AB.

Cancer Res. 2007 Nov 1;67(21):10538-45.


Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.

Sakakura K, Chikamatsu K, Furuya N, Appella E, Whiteside TL, Deleo AB.

Clin Immunol. 2007 Oct;125(1):43-51. Epub 2007 Jul 12.


Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.

Ito D, Visus C, Hoffmann TK, Balz V, Bier H, Appella E, Whiteside TL, Ferris RL, DeLeo AB.

Int J Cancer. 2007 Jun 15;120(12):2618-24.


Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.

Cicinnati VR, Zhang X, Yu Z, Ferencik S, Schmitz KJ, Dworacki G, Kaczmarek E, Oldhafer K, Frilling A, Baba HA, Schmid KW, Grosse-Wilde H, Broelsch CE, DeLeo AB, Gerken G, Beckebaum S.

Int J Cancer. 2006 Dec 15;119(12):2851-60.


Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL.

López-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, Ferrone S, Ferris RL.

J Immunol. 2006 Mar 15;176(6):3402-9.


Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.

Albers A, Abe K, Hunt J, Wang J, Lopez-Albaitero A, Schaefer C, Gooding W, Whiteside TL, Ferrone S, DeLeo A, Ferris RL.

Cancer Res. 2005 Dec 1;65(23):11146-55.


Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites.

Albers AE, Ferris RL, Kim GG, Chikamatsu K, DeLeo AB, Whiteside TL.

Cancer Immunol Immunother. 2005 Nov;54(11):1072-81. Epub 2005 Jun 16.


Pediatric upper airway endoscopy.

DeLeo A, Dimmitt P.

ORL Head Neck Nurs. 2005 Spring;23(2):29-30. Review. No abstract available.


Lower extremity joint coupling during running: a current update.

DeLeo AT, Dierks TA, Ferber R, Davis IS.

Clin Biomech (Bristol, Avon). 2004 Dec;19(10):983-91. Review.


Impact of p53-based immunization on primary chemically-induced tumors.

Cicinnati VR, Dworacki G, Albers A, Beckebaum S, Tüting T, Kaczmarek E, DeLeo AB.

Int J Cancer. 2005 Mar 1;113(6):961-70.


Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck.

Sirianni N, Ha PK, Oelke M, Califano J, Gooding W, Westra W, Whiteside TL, Koch WM, Schneck JP, DeLeo A, Ferris RL.

Clin Cancer Res. 2004 Oct 15;10(20):6929-37.


P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells.

Chikamatsu K, Albers A, Stanson J, Kwok WW, Appella E, Whiteside TL, DeLeo AB.

Cancer Res. 2003 Jul 1;63(13):3675-81.


Resident's case problem: diagnosis and treatment of posterolateral instability in a patient with lateral collateral ligament sprain.

DeLeo AT, Woodzell WW, Snyder-Mackler L.

J Orthop Sports Phys Ther. 2003 Apr;33(4):185-91; discussion 191-5. No abstract available.


The Electroencephalogram in Attention Deficit-Hyperactivity Disorder: Emphasis on Epileptiform Discharges.

Hughes JR, DeLeo AJ, Melyn MA.

Epilepsy Behav. 2000 Aug;1(4):271-277.


Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.

Hoffmann TK, Donnenberg AD, Finkelstein SD, Donnenberg VS, Friebe-Hoffmann U, Myers EN, Appella E, DeLeo AB, Whiteside TL.

Cancer Res. 2002 Jun 15;62(12):3521-9.


Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.

Stefanik DF, Fellows WK, Rizkalla LR, Rizkalla WM, Stefanik PP, Deleo AB, Welch WC.

J Neurooncol. 2001 Nov;55(2):91-100.


The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.

Hoffmann TK, Loftus DJ, Nakano K, Maeurer MJ, Chikamatsu K, Appella E, Whiteside TL, DeLeo AB.

J Immunol. 2002 Feb 1;168(3):1338-47.


Economic and health-related quality of life considerations of new therapies in Parkinson's disease.

Rubenstein LM, DeLeo A, Chrischilles EA.

Pharmacoeconomics. 2001;19(7):729-52. Review.


Brain oxygen tension during hyperoxia in a swine model of cerebral ischaemia.

Rossi S, Longhi L, Balestreri M, Spagnoli D, deLeo A, Stocchetti N.

Acta Neurochir Suppl. 2000;76:243-5.


Supplemental Content

Support Center